A high-valence bismuth(V) nanoplatform triggers cancer cell death and anti-tumor immune responses with exogenous excitation-free endogenous H<sub>2</sub>O<sub>2</sub>- and O<sub>2</sub>-independent ROS generation.

Tang, Yizhang; Yu, Xujiang; He, Liangrui; Tang, Meng; Yue, Wenji; Chen, Ruitong; Zhao, Jie; Pan, Qi et al. · Nat Commun · 2025

basic_science · Level V

Where this comes from

Abstract

Reactive oxygen species with evoked immunotherapy holds tremendous promise for cancer treatment but has limitations due to its dependence on exogenous excitation and/or endogenous H<sub>2</sub>O<sub>2</sub> and O<sub>2</sub>. Here we report a versatile oxidizing pentavalent bismuth(V) nanoplatform (NaBi<sup>V</sup>O<sub>3</sub>-PEG) can generate reactive oxygen species in an excitation-free and H<sub>2</sub>O<sub>2</sub>- and O<sub>2</sub>-independent manner. Upon exposure to the tumor microenvironment, NaBi<sup>V</sup>O<sub>3</sub>-PEG undergoes continuous H<sup>+</sup>-accelerated hydrolysis with •OH and <sup>1</sup>O<sub>2</sub> generation through electron transfer-mediated Bi<sup>V</sup>-to-Bi<sup>III</sup> conversion and lattice oxygen transformation. The simultaneous release of sodium counterions after endocytosis triggers caspase-1-mediated pyroptosis. NaBi<sup>V</sup>O<sub>3</sub>-PEG intratumorally administered initiates robust therapeutic efficacies against both primary and distant tumors and activates systemic immune responses to combat tumor metastasis. NaBi<sup>V</sup>O<sub>3</sub>-PEG intravenously administered can efficiently accumulate at the tumor site for further real-time computed tomography monitoring, immunotherapy, or alternative synergistic immune-radiotherapy. Overall, this work offers a nanomedicine based on high-valence bismuth(V) nanoplatform and underscores its great potential for cancer immunotherapy.

Medical subject headings